stockrow
Saturday 7 November 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024.
- Revenue
- +408.7%
- EPS
- +7.84%
- Free cash flow
- −21.3%
Quarter to June 2026, against a year earlier
31.15
2.15
+7.41%
Follow SRZN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 13 | — | 11 | 3 | 12 | (34.7%) | 11 | 2 | 1 | (37.0%) | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 100.00 | — | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | — | (33) | (55) | (36) | (43) | (64) | (242) | (332) | +49.2% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (288.03) | 0.00 | (596.56) | (6,960.77) | (2,885.33) | (6,960.8) pt | ||||||
| Net income | — | 0 | — | — | (33) | (55) | (36) | (43) | (64) | (242) | (332) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 5.40 | 0.00 | 3.63 | 0.47 | 0.99 | n/m | |||||
| Earnings | — | — | — | — | (30.71) | (33.13) | (15.59) | (21.33) | (21.67) | (32.37) | (37.39) | +1.1% | ||||||
| Cash flow | — | — | — | — | (27.31) | (29.64) | (19.08) | (20.00) | (6.01) | (4.04) | (2.98) | (31.8%) | ||||||
| Capex | — | — | — | — | (0.82) | (0.77) | (0.31) | (0.20) | (0.01) | (0.02) | (0.02) | (53.9%) | ||||||
| Free cash flow | — | — | — | — | (28.13) | (30.41) | (19.39) | (20.20) | (6.02) | (4.06) | (3.00) | (32.1%) | ||||||
| Book value | — | — | — | — | 44.39 | 66.61 | 32.84 | 18.80 | (7.29) | (25.11) | (18.75) | n/m | ||||||
| Shares, m | — | — | — | — | 1 | 2 | 2 | 2 | 3 | 7 | 10 | +47.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | — | 0.00 | 48.61 | 31.56 | 16.2 | ||||||
| P/B | — | — | — | — | — | — | 0.26 | — | 0.00 | 0.00 | 0.00 | 0.1 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | 0.00 | 22.94 | 22.70 | 7.6 | ||||||
| EV/FCF | — | — | — | — | — | — | 1.26 | — | (0.43) | (2.63) | (7.47) | (0.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (29) | (49) | (44) | (40) | (18) | (30) | (35) | +0.8% | |||||
| Capex | — | — | — | — | (1) | (1) | (1) | 0 | 0 | 0 | 0 | (31.9%) | ||||||
| Free cash flow | — | — | — | — | (30) | (50) | (45) | (41) | (18) | (30) | (35) | +0.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 43 | 92 | 72 | 34 | 32 | 82 | 100 | +13.7% | |||||
| Net debt | — | — | — | — | (49) | (102) | (76) | (36) | (35) | (89) | (102) | +12.7% | ||||||
| Shareholders’ equity | — | — | — | — | 47 | 110 | 76 | 38 | (21) | (188) | (219) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (105.43) | (54.86) | (31.78) | (63.52) | (134.46) | (328.86) | (304.47) | (223.4) pt | |||||
| ROIC | — | — | — | — | 0.00 | (433.10) | (17,001.15) | (1,512.29) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | (32.72) | (69.62) | (38.78) | (75.55) | (767.91) | 231.45 | 387.44 | +264.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 3 | 83 | 74 | 42 | 41 | 44 | — | +71.1% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.17 | 0.00 | 0.26 | 0.08 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Surrozen, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RZLT Rezolute, Inc. | $352.1M | — (loss-making) | — | — | n/m | +40.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTNM Contineum Therapeutics, Inc. | $345.9M | — (loss-making) | — | — | n/m | +10.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MPLT MapLight Therapeutics, Inc. | $345.7M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | Compare |
| AGMB AgomAb Therapeutics NV | $343.3M | — | — | — | — | — | — | — | Compare |
| SRZN Surrozen, Inc. | $340.9M | — (loss-making) | — (loss-making) | +408.65% (above 0%: growing) | n/m | −21.25% (below 0%: shrinking) | 100.00% | (207.40%) | |
| AVIR Atea Pharmaceuticals, Inc. | $338.5M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OBIO Orchestra BioMed Holdings, Inc. | $337.8M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $335.4M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| IRD Opus Genetics, Inc. | $333.2M | — (loss-making) | — (loss-making) | −73.80% (below 0%: shrinking) | n/m | −16.37% (below 0%: shrinking) | 100.00% | (2,182.78%) | Compare |
| Median of peers | $340.9M | — | — | +22.29% | — | +10.04% | 63.40% | 0.00% |
Pay and ownership Proxy statement filed 1 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.82m | 4.81m | 240.43 |
| 2024 | 1.52m | 1.93m | 152.66 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement